An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma

Published: 03-03-2009
Last updated: 06-05-2024

The primary objective is to determine the effect on progression-free survival (PFS) of adding MORAb-009 to the combination of pemetrexed and cisplatin in the treatment of subjects with unresectable malignant pleural mesothelioma (MPM). (Protocol ch...

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Mesotheliomas
Study type	Interventional

Summary

ID

NL-OMON37190

Source
ToetsingOnline

Brief title
MORAb-009 in patients with mesothelioma

Condition

- Mesotheliomas

Synonym
asbestosis, pleural cancer

Research involving
Human

Sponsors and support

Primary sponsor: Morphotek Inc

Source(s) of monetary or material Support: Biofarmaceutisch bedrijf (sponsor)

Intervention

Keyword: Cisplatin, mesothelioma, MORAb-009, Pemetrexed

Outcome measures

Primary outcome

The primary efficacy endpoint is PFS at 6 months. PFS is defined as time from the date of first dose of MORAb-009 to the date of disease progression or death due to any cause. A *response*, in terms of PFS, is defined to be at least a 6 month stabilization of disease.

Safety endpoints (protocol 9.6, page 66) include

- assessment of incidence and severity of AEs, including clinical laboratory parameters, physical examination, ECG, pulmonary function testing and HACA development.

- Tolerability of treatment: The number of subjects discontinuing treatment due to toxicity and the number of subjects who delay treatment or skip all or part of cycles of treatment due to toxicity and the extent of delays.

Secondary outcome

Secundary efficacy endpoints are (protocol 9.5, page 66):

- ORR (defined as the proportion of subjects with a partial response (PR) or complete response (CR))

- duration of this response (defined as as the time from first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause)

- overall survival (defined as the time from the date of the first dose of

MORAb-009 to the date of death)

- overall median progression free survival

- To determine the safety and tolerability of MORAb-009 when administered with

pemetrexed and cisplatin.

Exploratory endpoints:

- Change in CA-125 Levels

- Change in Karnofsky Performance Status

- Analysis of survival by HLA subtype (if sufficient data on HLA subtype are

available)

- Molecular marker analysis

Study description

Background summary

Mesothelioma is an aggressive malignancy that is almost uniformly fatal, with a median survival of approximately 9-12 months. The regimen of pemetrexed plus cisplatin is now the standard of care for newly diagnosed subjects with mesothelioma. Although this regimen represents a significant advance in the treatment of mesothelioma, the median survival of subjects is only 12.1 months and there is clearly a need to develop better therapeutic regimens to improve the outcome of these subjects. Given the fact that MORAb-009 was generally well-tolerated in the Phase 1 study and the possibility of clinical benefit in mesothelin-positive tumors, this Phase 2 study of the efficacy of MORAb-009 in combination with conventional chemotherapeutic agents in unresectable MPM is being undertaken. (Protocol 3.2, page 24.)

Study objective

The primary objective is to determine the effect on progression-free survival (PFS) of adding MORAb-009 to the combination of pemetrexed and cisplatin in the

treatment of subjects with unresectable malignant pleural mesothelioma (MPM). (Protocol ch 2, page 22.)

Study design

See figure 1, page 25 of the protocol for the protocol schema. If a patient will be eligible for the study, a maximum of 6 21-day cycles of the combination treatment MORAb-009, CIsplatin and Pemetrexed will be administered. MORAb-009 will be administered on day 1 and 8 of every cycle, Pemetrexed and Cisplatin on day 1 of every cycle.
After the combination treatment, patients can continue MORAb-009 monotherapy until disease progression. Hereafter, only an 'End of Treatment' visit will be scheduled. Subjects will be contacted monthly for the first 9 months and every other month thereafter for survival status and any new anti-cancer therapies until death or the end of the trial.

Intervention

All patients will receive intravenous MORAb-009 in a dose of 5.0 mg/kg on day 1 and 8 of every cycle. Pemetrexed will be intravenously administered at a dose of 500 mg/m2 in approximately 10 minutes. The protocol describes how the chemotherapy should be administered, but the centres are allowed to use their local standard practice for this. Approximately 30 minutes thereafter the intravenous Cisplatin infusion will commence at a dose of 75 mg/m2. This infusion will take ppproximately 2 hours.

Study burden and risks

Refer to the flow chart page 56 for an overview of all study procedures. Refer to section E of the ABR form for an overview of the burden and risks associated with participation.

Contacts

Public
Morphotek Inc

210 Welsh Pool Road
Exton PA 19341
US
Scientific
Morphotek Inc

210 Welsh Pool Road

Exton PA 19341
US

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

- >= 18 years of age
- Life expectancy of at least 3 months
- Confirmed diagnosis of MPM with the following characteristics: unresectable disease (or otherwise not a candidate for curative surgery); or epithelial type or biphasic (mixed) type with low sarcomatous content).
- Measurable disease at Screening
- Karnofsky performance status of >= 70% at Screening
- Other significant medical conditions must be well-controlled and stable
- Laboratory results must be within a certain range (see page 26)
- serum creatinine clearance >= 60 mL/min
- Subjects must be sterile or using adequate contraception during the study and for at least 8 weeks after the last dose of MORAb-009
- willing and able to sign informed consent

Exclusion criteria

- Sarcomatous type of mesothelioma
- Prior systemic therapy or radiotherapy
- central nervous system (CNS) tumor involvement
- other active malignancy requiring treatment
- clinically significant heart disease or arrhythmias
- hepatitis or HIV infection
- active serious systemic disease
- Treatment within 3 months of the start of the trial with other immunomodulatory therapy

- hypersensitivity to one of the medications which will be administered
- breast-feeding, pregnant, or likely to become pregnant
- not willing or unable to sign informed consent

Study design

Design

Study phase:	2
Study type:	Interventional
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	16-02-2010
Enrollment:	6
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	Alimta
Generic name:	Pemetrexed
Registration:	Yes - NL intended use
Product type:	Medicine
Brand name:	Cisplatin
Generic name:	Cisplatin
Registration:	Yes - NL intended use
Product type:	Medicine
Brand name:	High-affinity monoclonal IgG1 1/k antibody
Generic name:	MORAb-009

Ethics review

Approved WMO Date:	03-03-2009
Application type:	First submission
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	17-09-2009
Application type:	First submission
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	06-10-2009
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	17-11-2009
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	23-11-2009
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	25-02-2011
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	31-05-2011
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO	

Date:	22-06-2011
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	13-12-2011
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	29-12-2011
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	16-01-2012
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	05-06-2012
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	25-06-2012
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	16-05-2013
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)
Approved WMO Date:	11-06-2013
Application type:	Amendment
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam

(Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2008-005448-18-NL
ClinicalTrials.gov	NCT00738582
CCMO	NL26231.078.09